8-K: Tenax Therapeutics Q3 2025: LEVEL Study Progress, Patent Grant

Tenax Therapeutics reported Q3 2025 financial results, highlighted progress in its Phase 3 LEVEL study, and announced a key European patent grant for TNX-103.

Summary

• Reported a net loss of $15.8 million for the third quarter ended September 30, 2025, compared to a net loss of $4.0 million for the same period in 2024.
• Cash and cash equivalents stood at $99.4 million as of September 30, 2025, with an expectation to fund operations through 2027.
• Research and development (R&D) expenses increased to $10.3 million in Q3 2025 from $3.1 million in Q3 2024, primarily due to increased clinical development costs for the Phase 3 LEVEL and LEVEL-2 studies and higher R&D employee headcount.
• General and administrative (G&A) expenses rose to $6.5 million in Q3 2025 from $1.5 million in Q3 2024, mainly driven by increased non-cash stock-based compensation expense and higher legal and professional fees.
• The European Patent Office (EPO) notified an intention to grant a patent for levosimendan in PH-HFpEF, providing intellectual property protection until December 2040, with potential for extension.
• Enrollment in the Phase 3 LEVEL study of TNX-103 in PH-HFpEF is progressing well, with enrollment completion (230 patients) expected in the first half of 2026 and topline data anticipated in the second half of 2026.
• The company remains on track to initiate a second global registrational Phase 3 study, LEVEL-2, in PH-HFpEF in 2025, having qualified over 160 investigative sites across 15 countries.
• Tenax will host a virtual Key Opinion Leader (KOL) call on November 13, 2025, to discuss the PH-HFpEF treatment landscape and TNX-103 programs.

Sentiment

Score: 6

Explanation: While the company reported a significant increase in net loss and operating expenses, this is largely attributable to increased R&D investment in advancing two Phase 3 clinical trials, which is typical for a development-stage pharmaceutical company. The positive clinical progress, strong cash position expected to last through 2027, and the recent European patent grant for a key indication provide a positive outlook despite the short-term financial burn.

Positives

• The European Patent Office (EPO) notified an intention to grant a patent for levosimendan in PH-HFpEF, securing intellectual property protection until December 2040, with potential for further extension via supplementary protection certificates (SPCs).
• Enrollment in the Phase 3 LEVEL study of TNX-103 is progressing well, demonstrating high rates of study and therapy continuation through both blinded and open-label extension stages.
• On track to complete enrollment of 230 patients in the Phase 3 LEVEL study in the first half of 2026.
• On track to initiate a second global Phase 3 study, LEVEL-2, in PH-HFpEF in 2025.
• Over 160 investigative sites across 15 countries have been qualified for the upcoming LEVEL-2 study, indicating strong global preparation.
• Cash and cash equivalents of $99.4 million as of September 30, 2025, are expected to fund the company through 2027, providing a solid financial runway.

Negatives

• Net loss significantly increased to $15.8 million for Q3 2025, compared to $4.0 million for Q3 2024, representing a 295% increase.
• Research and development expenses rose to $10.3 million in Q3 2025 from $3.1 million in Q3 2024, a 232% increase, indicating a higher burn rate.
• General and administrative expenses increased to $6.5 million in Q3 2025 from $1.5 million in Q3 2024, a 333% increase, primarily due to non-cash stock-based compensation and increased legal/professional fees.
• Net loss per share, basic and diluted, was $(0.40) for Q3 2025, compared to $(0.19) for Q3 2024.

Risks

• Risks associated with clinical trials, including timing, delays, costs, design, location, initiation, enrollment, and results.
• Intellectual property risks.
• Potential delays in regulatory review and approval of product candidates in development.
• Risks related to business strategy, including the prioritization and development of product candidates.
• Uncertainty regarding estimates of the potential market opportunity for product candidates.
• Reliance on third parties, including Orion Corporation, manufacturers, and Contract Research Organizations (CROs).
• Risks concerning the formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• Competitive position in the market.
• Ability to maintain company culture and recruit, integrate, and retain qualified personnel and advisors.
• Risks associated with cash needs.
• Volatility and uncertainty in the global economy and financial markets due to unexpected changes in tariffs, possibility of pandemics, global financial and geopolitical uncertainties (e.g., Middle East, Russian invasion of Ukraine).
• Changes in legal, regulatory, and legislative environments in operating markets, including impacts from government shutdowns, affecting the ability to obtain regulatory approval for products.

Future Outlook

Tenax Therapeutics expects to complete enrollment of 230 patients in the Phase 3 LEVEL study in the first half of 2026, with topline data anticipated in the second half of 2026. The company remains on track to initiate the global Phase 3 LEVEL-2 study in 2025. Cash and cash equivalents are projected to fund operations through 2027.

Management Comments

• "We continued to advance our lead program, TNX-103, in patients with PH-HFpEF and remain on track to enroll 230 patients in the ongoing Phase 3 LEVEL study in the first half of 2026, and initiate the global LEVEL-2 study this year."
• "PH-HFpEF is a debilitating, often fatal disease and the most common form of pulmonary hypertension, yet no drugs are approved for this indication."
• "We look forward to our upcoming virtual KOL call with some of the leading minds in this field, who intend to discuss the physiology of PH-HFpEF, the strategy for using levosimendan to alleviate symptoms and improve exercise ability, and how this product is differentiated from other efforts to develop medicines for Group 2 PH patients."

Industry Context

PH-HFpEF is identified as a debilitating, often fatal disease and the most common form of pulmonary hypertension, with no currently approved drugs. This positions Tenax Therapeutics' TNX-103 (levosimendan) as a potential first-in-class therapy addressing a significant unmet medical need. Levosimendan's existing market authorization in 60 countries for acutely decompensated heart failure suggests a known safety profile and mechanism, which could de-risk its development for PH-HFpEF, differentiating it from novel compounds.

Comparison to Industry Standards

• The filing explicitly states that PH-HFpEF is an indication for which no drugs are currently approved, positioning TNX-103 as a potential first-in-class therapy.
• Levosimendan (TNX-101, TNX-102, TNX-103) has received market authorization in 60 countries for intravenous use in acutely decompensated heart failure, indicating a proven efficacy and safety profile in a related cardiovascular condition, which is a strong benchmark for drug development.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through clinical trial success and intellectual property protection, but also face short-term risks from increased operational losses and the inherent uncertainties of drug development.
• Patients (PH-HFpEF): Continued progress towards a potential first-in-class treatment for a severe and currently untreatable disease offers hope for improved health outcomes.
• Employees: Increased R&D headcount suggests growth and stability in research and development roles.
• Regulatory Authorities: Ongoing Phase 3 studies will eventually lead to submissions for regulatory approval, requiring their review and oversight.

Next Steps

• Host a virtual KOL call on Thursday, November 13, 2025, at 4:30 p.m. ET.
• Initiate the second registrational Phase 3 study, LEVEL-2, in patients with PH-HFpEF in 2025.
• Complete enrollment of 230 patients in the Phase 3 LEVEL study in the first half of 2026.
• Release topline data from the Phase 3 LEVEL study in the second half of 2026.

Key Dates

Recommendation

Tenax Therapeutics is making significant clinical progress with two Phase 3 studies for PH-HFpEF, an indication with a high unmet medical need. This progress is supported by a strong cash position, expected to fund operations through 2027, and a recent European patent grant extending intellectual property protection. However, the substantial increase in net loss and operating expenses reflects the high burn rate typical of a development-stage biotech. The stock remains speculative, heavily tied to future clinical trial success and regulatory approvals. A 'Hold' recommendation acknowledges the positive operational developments and financial runway while recognizing the inherent risks and increased cash consumption.

Keywords

Tenax Therapeutics, TENX, PH-HFpEF, levosimendan, TNX-103, LEVEL study, LEVEL-2 study, pulmonary hypertension, heart failure, clinical trial, pharmaceutical, biotech, Q3 2025, financial results, patent, intellectual property